TargetBeta
CALCR
calcitonin receptor · also CTR, CT-R · Calcitonin receptors
7 programs in company-led studies act on CALCR, from 4 companies: 3 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| zenagamtide | Novo Nordisk | phase 3 | 3526 running | GLP1R | a judged reading |
| cagrilintide | Novo Nordisk | phase 3 | 5018 running | – | a judged reading |
| petrelintiderule | Zealand Pharma | phase 3 | 115 running | – | the studies' text |
| ABBV-295 | AbbVie | phase 2 | 54 running | – | the company's pipeline |
| PF-08653945 | Pfizer | phase 2 | 22 running | – | the company's pipeline |
| CagriSema A | Novo Nordisk | phase 1 | 10 running | GLP1R | a judged reading |
| GUB014295 | AbbVie | phase 1 | 10 running | – | the company's pipeline |
Also acted on by the same programs
Conditions their studies are in
- Obesity, 6 programs
- Diabetes Mellitus, Type 2, 2 programs
- Overweight, 2 programs
- Cardiovascular Diseases, 1 program
- Diabetes Mellitus, 1 program
- Hypertension, 1 program
- Psoriasis, 1 program
- Renal Insufficiency, 1 program
- Renal Insufficiency, Chronic, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026ABBV-295 · AbbVie · phase 2 · NCT07514260
- Jan 13, 2027PF-08653945 · Pfizer · phase 2 · NCT07725809
- Mar 1, 2027cagrilintide · Novo Nordisk · phase 3 · NCT07011667
- Apr 12, 2027petrelintide · Zealand Pharma · phase 3 · NCT07682818
- Nov 11, 2027zenagamtide · Novo Nordisk · phase 3 · NCT07535307
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.